CTOs on the Move

Medcura Incorporated

www.medcurainc.com

 
Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, Medcura`s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medcurainc.com
  • 5650 Rivertech Court Suite South
    Riverdale, MD USA 20737
  • Phone: 240.684.8801

Executives

Name Title Contact Details

Similar Companies

Ginkgo Bioworks

At Ginkgo Bioworks we are expanding the role of biology in our world.Nature`s biodiversity holds answers to challenges in health, energy, food, materials, and more. Organism Engineers at Ginkgo learn from Nature to develop new organisms that replace technology with biology.

Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.

Westbridge Agricultural Products

Through safe agricultural, home and garden products and technologies, Westbridge is cultivating environmental awareness.

Alternatives Technologies Pharma

Alternatives Technologies Pharma Inc. is a Chicoutimi, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affinivax

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children`s Hospital.